Artivion, Inc. · NYSE:AORT

Artivion — Investor Presentation (August 2026)

23 slides from Artivion's investor presentation, August 2026

  1. Slide 1: Corporate Overview

    Corporate Overview August 2026 © 2026 Artivion, Inc. 1

  2. Slide 2: Forward-Looking Statement

    FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management’s beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect

  3. Slide 3: An Aortic Disease-Focused Company

    AN AORTIC DISEASE-FOCUSED COMPANY ~$444 MILLION FY25 REVENUE; ~$90 MILLION FY25 EBITDA AORTIC VALVE STENOSIS <65 YRS ALLOGRAFT MECHANICAL VALVES VALVES AORTIC DISSECTION & ANEURYSMS Aneurysm SURGICAL STENT SEALANT GRAFTS Dissection © 2026 Artivion, Inc. 3

  4. Slide 4: Experienced Leaders

    EXPERIENCED LEADERS Decades of combined experience and leadership in the medical device industry Lance Berry John Davis Jean Holloway Simona Zannetti EVP, COO & CFO Chief Commercial Officer SVP, GC, CCO & CS SVP, Clinical Research & Chief Medical Officer Pat Mackin Chairman, President & CEO Previous

  5. Slide 5: Opportunity Overview

    OPPORTUNITY OVERVIEW Leveraging the Most Comprehensive Aortic-Focused Portfolio in Healthcare for Durable Revenue Growth and EBITDA Margin Expansion​ Highly Differentiated Aorta Expert Global Sales Force Limited Competition with Focused Products in Focused End Markets High Barriers to Entry Technolo

  6. Slide 6: Driving Sustained Double-Digit Revenue Growth & 2x+ EBITDA Growth

    DRIVING SUSTAINED DOUBLE-DIGIT REVENUE GROWTH & 2x+ EBITDA GROWTH Highly Differentiated, High Growth, Gross Margin Highly Defendable High Margin Expansion + Double Digit Base Business Businesses SG&A Leverage Revenue Growth Stent 2x+ Preservation  Gross margin Services Grafts expansion through mix

  7. Slide 7: Highly Differentiated, Highly Defendable Base Business

    HIGHLY DIFFERENTIATED, HIGHLY DEFENDABLE BASE BUSINESS Strong Positions in Segments with Limited Competition and No Anticipated New Entrants Market 2025 # Major Growth Differentiation Global TAM Position/ Revenue Competitors Profile Share Only Preservation Mid Decellularized Services $96M $150M #1 /

  8. Slide 8: On-X Aortic Heart Valve

    ON-X AORTIC HEART VALVE POST APPROVAL STUDY (PAS) VS. PROACT IDE 5-year real-world results demonstrate even better patient outcomes than predicted by the On-X aortic heart valve PROACT IDE study COMPOSITE PRIMARY ENDPOINT Only Mechanical 5.39% vs 1.83%, p<0.0001; N=229 Heart Valve Maintained at a Lo

  9. Slide 9: On-X: High Growth, High Margin, with Market Upside

    On-X: HIGH GROWTH, HIGH MARGIN, WITH MARKET UPSIDE New Recently Published Data Across Three Leading Journals to Drive Potential $100 million Upside to Addressable U.S. Mechanical Heart Valve Market 5-year PAS Data Presented in April 20241  Demonstrated 87% Reduction in Major Bleeding  Validated On

  10. Slide 10: On-X: Significant Market Opportunity for Profitable, Cash Generating Product Line

    On-X: SIGNIFICANT MARKET OPPORTUNITY FOR PROFITABLE, CASH GENERATING PRODUCT LINE Current On-X Remaining Mechanical BPV <65 Market Total Global On-X Business Valve Market Opportunity Expansion Opportunity Market Opportunity ~$150M ~$400M  Only mechanical heart valve indicated for Low INR of 1.5– 2.

  11. Slide 11: High Growth Stent Graft Business

    HIGH GROWTH STENT GRAFT BUSINESS  Focused on More Complex, Less Competitive Segments  Artivion Stent Graft Growth: 18% 3-year CAGR1 Advanced Stent Graft Segment Mature Stent Graft Segment MARKET GROWTH RATE: MID-TEENS MARKET GROWTH RATE: MID-SINGLE DIGITS Frozen Elephant Trunk (E-vitaTM Open Neo)

  12. Slide 12: U.S. Complex Aortic Arch Market Portfolio

    U.S. COMPLEX AORTIC ARCH MARKET PORTFOLIO Innovation Leader in Space with Acceptable Reimbursement; New MS-DRG Code 209, effective October 1, 2025 Arcevo LSA NEXUS ONE Pivotal Trial Enrolling​ PMA Approved; Recently Acquired AMDS NEXUS DUO / TRE PMA Approved PMA Pipeline NEXUS Ascending NEXUS LSA PM

  13. Slide 13: Aortic Arch Focused R&D Pipeline

    AORTIC ARCH FOCUSED R&D PIPELINE Step Function Revenue/EBITDA Growth Catalysts via Multipronged PMA Pipeline of High Margin Products​ Regulatory Path 2025 2026 2027 2028 2029 2030 2031 2032+ Hybrid Dissection Prosthesis US PMA Approved AMDS in June 2026 Endovascular Arch Branch US PMA Approved in Ap

  14. Slide 14: Early U.S. Launch of AMDS Hybrid Prosthesis

    EARLY U.S. LAUNCH OF AMDSTM HYBRID PROSTHESIS  High growth, high margin business with limited competitive alternatives  PMA approved in June 2026  Strong reordering patterns reflect positive user experience supported by growing body of evidence  New MS-DRG Code 209, effective October 1, 2025 $15

  15. Slide 15: AMDS PERSEVERE US IDE Study

    AMDSTM PERSEVERE US IDE STUDY Full IDE data demonstrates AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control ACUTE DEBAKEY TYPE I (ADTI) Through Hospital WITH MALPERFUSION Full 30-Day Discharge Data Data Hemiarch Reference Cohort Avg.¹ (n=790) PERSEVERE² (n=

  16. Slide 16: TRIOMPHE IDE Trial Demonstrates Safety & Effectiveness

    TRIOMPHE IDE TRIAL DEMONSTRATES SAFETY & EFFECTIVENESS FDA Approved for the endovascular treatment of chronic dissections involving the aortic arch who are high risk for open surgical repair 30-DAY N=60 (Co-Primary Performance Goal p Value 1-YEAR Endpoints) PMA Approved in Clinical Failure1 15.0% 35

  17. Slide 17: ARTIZEN Pivotal IDE Study

    ARTIZEN PIVOTAL IDE STUDY Prospective, Non-randomized, Non-blinded, Double-arm, Multicenter (US & EU ≈ 30 Sites) PRIMARY PATIENT GROUP • 117 patients: Chronic dissection or Aneurysm • Primary endpoint: Freedom from major adverse events (MAEs) within 1-year post-index procedure: all-cause mortality,

  18. Slide 18: New Long-Term Study Shows Excellent Survival & Durability with the Ross Procedure

    NEW LONG-TERM STUDY SHOWS EXCELLENT SURVIVAL & DURABILITY WITH THE ROSS PROCEDURE Published in JACC: Journal of The American College of Cardiology in June 2026 STUDY DESIGN • 455 consecutive adult Ross procedures at a single high-volume Ross center from Actuarial Survival After the 2011–2019; 95% (n

  19. Slide 19: Differentiated Business Model with Highly Leverageable Global Infrastructure

    DIFFERENTIATED BUSINESS MODEL WITH HIGHLY LEVERAGEABLE GLOBAL INFRASTRUCTURE Significant EBITDA Margin Expansion Opportunity Gross Margin Scalable Global Leverageable Global Reinvesting in R&D Expansion Sales Force G&A Infrastructure Highly Accretive Product ~200 Global Direct Sales Consistent inves

  20. Slide 20: Full Year 2026 Revenue Guidance

    FULL YEAR 2026 REVENUE GUIDANCE GROWTH DRIVERS + Continued strength in existing products On-X and aortic stents $90.0M + Positive new data supporting the benefits of AMDS and On-X aortic valves $480M- Revenue* ($) $443.6M $496M + Continued adoption of AMDS following Y/Y cc. 13% 7-11% receipt FDA PMA

  21. Slide 21: Revenue Growth and Operating Leverage to Drive Adjusted EBITDA Expansion

    REVENUE GROWTH AND OPERATING LEVERAGE TO DRIVE ADJUSTED EBITDA EXPANSION FULL YEAR 2026 ADJUSTED EBITDA EXPECTATIONS* DRIVERS Expect continued operating leverage to be $90.0M driven by gross margin expansion, global sales force and G&A infrastructure Adjusted $89.6M $92M- EBITDA ($) $99M *Now includ

  22. Slide 22: Investment Highlights

    INVESTMENT HIGHLIGHTS  Category-defining products & expanding aortic market leadership  Global infrastructure with substantial leverage opportunity  Concentrated end markets with expert sales organization  Base business driving consistent and sustainable free cash flow  High-margin, low-competi

  23. Slide 23: © 2026 Artivion, Inc.

    © 2026 Artivion, Inc.

Artivion — Investor Presentation (August 2026) on 6ix